Skip to main content

Advertisement

SpringerLink
Log in

Predictive factors for low rate of remission in a population of Colombian patients with severe proliferative lupus nephritis

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

The objective of this study is to determine the predictive risk factors of failure to achieve remission within 12 months in a group of patients with proliferative lupus nephritis from Northwestern Colombia. Pragmatic clinical study with retrospective analysis was conducted. We included subjects with systemic lupus erythematosus as defined by the American College of Rheumatology with biopsy-proven nephritis. We assessed 149 patients, with 84 % female. Age at diagnosis of systemic lupus erythematosus is 24.7 years (16–31). The time between diagnosis of lupus erythematosus and proliferative nephritis is 2 months (0–35.5). ISN/RPS 2003 histologic classification types are the following: IV (63.8 %), III (13.4 %), V + III (3.3 %), and V + IV (3.3 %). Activity index is 6.18 ± 4.55 and chronicity index is 1 (0–3). The result of 24-h proteinuria is 2000 mg (667–4770) and baseline creatinine is 0.9 mg/dL (0.7–1.3). Induction therapy includes corticosteroids (100 %), cyclophosphamide (74.1 %), and mycophenolate mofetil (25.9 %). At 12 months, 40.7 % of individuals failed to attain partial or complete remission. Elevated creatinine (p = 0.0001) and 24-h proteinuria greater than 1500 mg (p = 0.0011) were basal predictors of failure to attain partial or complete remission by bivariate analysis. Similar results were obtained in multivariate analysis: Baseline creatinine elevation (OR 3.62, 95 % CI, 1.59–8.23; p = 0.002) and 24-h proteinuria greater than 1500 mg (OR 3.62, 95 % CI, 1.29–10.13; p = 0.014) were independent predictors of failure to achieve partial or complete remission. At 12 months, 40.7 % of patients did not attain partial or complete remission. Baseline elevated creatinine and 24-h proteinuria over 1500 mg were predictors for poor response.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Pons-Estel B, Catoggio L, Cardiel M, Soriano E, Gentiletti S, Villa A (2004) The GLADEL multinational Latin American prospective inception cohort of 1,214 patient with systemic lupus erythematosus. Medicine 83:1–18

    Article  PubMed  Google Scholar 

  2. López P, Mozo L, Gutiérrez C, Suárez A (2003) Epidemiology of systemic Lupus erythematosus in a Northern Spanish population: gender and age influence on immunological features. Lupus 12:860–865

    Article  PubMed  Google Scholar 

  3. Arbuckle MR, James JA, Dennis GJ, Rubertone MV, McClain MT, Kim XR et al (2003) Rapid clinical progression to diagnosis among African-American men with systemic lupus erythematosus. Lupus 12:99–106

    Article  CAS  PubMed  Google Scholar 

  4. Bertoli A, Alarcón GS, Calvo-Alen J, Fernández M, Vila L, Reveille J (2006) For the LUMINA study group. systemic lupus erythematosus in a U.S. multiethnic cohort: clinical features, course and outcome in patients with late-onset disease. Arthritis Rheum 54:1560–1567

    Google Scholar 

  5. Ramírez-Gómez LA, Uribe-Uribe O, Osío-Uribe O, Grisales-Romero H, Cardiel MH, Wojdla D et al (2008) Systemic lupus erythematosus in childhood Latin America. The GLADEL experience in 230 children. Lupus 17:596–604

    Article  PubMed  Google Scholar 

  6. Pinto LF, Guerra L, González JR, Pérez A, Velásquez CJ, Felipe O et al (1997) Lupus eritematoso sistémico: análisis clínico en una población de Medellín. Rev Colomb Reumatol 4:170–173

    Google Scholar 

  7. Senior JM, Pinto LF, Uribe O, De la Cruz OF, Ramírez LA (1994) Nefritis lupica: correlación clinicopatológica y respuesta a pulsos de ciclofosfamida. Rev Colomb Reumatol 1:19–27

    Google Scholar 

  8. Ramírez-Gómez LA, Builes CA, Maya C, Palacio CA, Velásquez JF, Uribe O (1998) Lupus eritematoso sistémico en niños. Rev Colomb Reumatol 5:11–17

    Google Scholar 

  9. Martins L, Rocha G, Rodrigues A, Santos J, Vasconcelos C, Correia J et al (2002) Lupus nephritis: a retrospective review of 78 cases from a single center. Clin Nephrol 57:114–119

    Article  CAS  PubMed  Google Scholar 

  10. Mac Gowan JR, Ellis S, Griffiths M, Isenberg DA (2002) Retrospective analysis of outcome in a cohort of patients with lupus nephritis treated between 1997 and 1999. Rheumatology 41:981–987

    Article  CAS  Google Scholar 

  11. Ortega LM, Schultz DR, Lenz O, Pardo V, Contreras GN (2010) Lupus nephritis: pathologic features, epidemiology and guide to therapeutic decisions. Lupus 19:567–574

    Article  Google Scholar 

  12. Austin HA III, Boumpas D, Vaughan M, Ballow J (1994) Predicting renal outcomes in severe lupus nephritis: contribution of clinical and histologic data. Kidney Int 45:544–550

    Article  PubMed  Google Scholar 

  13. Austin HA III, Boumpas DT, Vaughan EM, Ballow JE (1995) High -risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients. Nephrol Dial Transplant 10:1620–1628

    PubMed  Google Scholar 

  14. CA A -S, Villa AR, Martínez-Rueda JO, Muñoz L, Cardiel MH, Alcocer-Varela J (1995) Factors associated with chronic renal failure in 121 patients with lupus nephritis: a case-control study. Lupus 4:197–203

    Article  Google Scholar 

  15. Korbet S, Lewis E, Schwartz M, Reichlin M, Evans J, Rohde R et al (2000) Factors predictive of outcome in severe lupus nephritis. Am J Kidney Dis 35:904–914

    Article  CAS  PubMed  Google Scholar 

  16. Mok CC, Ho CT, Chan KW, Lau CS, Wong RW (2002) Outcome and prognostic indicators on diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine. Arthritis Rheum 46:1003–1013

    Article  CAS  PubMed  Google Scholar 

  17. Mok CC (2005) Prognostic factors in lupus nephritis. Lupus 14:39–44

    Article  CAS  PubMed  Google Scholar 

  18. Flower C, Hennis A, Hambleton IR, Nicholson G (2006) Lupus nephritis in an Afro-Caribbean population: renal indices and clinical outcomes. Lupus 15:689–694

    Article  CAS  PubMed  Google Scholar 

  19. Gibson K, Gipson D, Massengill S, Dooley MA, Primack W, Ferris M et al (2009) Predictors of relapse and end stage kidney disease in proliferative lupus nephritis: focus on children, adolescents and young adults. Clin J Am Soc Nephrol 4:1962–1967

    Article  PubMed Central  PubMed  Google Scholar 

  20. Moon SJ, Kwok SK, Ju JH, Park KS, Park SH, Cho CS et al (2011) Predictors of chronic kidney disease in Korean patients with lupus nephritis. J Rheumatol 38:2588–2597

    Article  PubMed  Google Scholar 

  21. Contreras G, Pardo V, Cely C, Borja E, Hurtado A, De la Cuesta C (2005) Factors associated with poor outcomes in patients with lupus nephritis. Lupus 14:890–895

    Article  CAS  PubMed  Google Scholar 

  22. Vozmediano C, Rivera F, López-Gómez JM, Hernández D (2012) On behalf of all members of the Spanish Registry of Glomerulonephritis. Extra Nephron 2:269–277

    Article  Google Scholar 

  23. Appel GB, Contreras G, Dooley MA (2009) Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20:1103–1112

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Dooley MA, Jayne D, Ginzler E, Isenberg D, Olsen N, Wofsy D et al (2011) Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 365:1886–1895

    Article  CAS  PubMed  Google Scholar 

  25. Levey AS, Lan SP, Corwin HL, Kasinath BS, Lachin J, Neilson EG et al (1992) Progression and remission of renal disease in the Lupus Nephritis collaborative study: results of treatment with prednisone and short-term oral cyclophosphamide. Ann Int Med 116:114–123

    Article  CAS  PubMed  Google Scholar 

  26. Fraenkel L, Hayslett JP, Esdaile JM (1994) Response to treatment as a predictor of long-term outcome in patients with lupus nephritis. J Rheumatol 21:2052–2057

    CAS  PubMed  Google Scholar 

  27. Houssiau F, Vasconcelos C, D’ Cruz D, Sebastian GD, Garrido ER, Danieli MG (2004) Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis. Lessons from long term follow-up of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 50:3934–3940

    Article  PubMed  Google Scholar 

  28. So MW, Koo BS, Kim YG, Lee CK, Yoo B (2011) Predictive value of remission status after 6-months induction therapy in patients with proliferative lupus nephritis: a retrospective analysis. Clin Rheumatol 30:1399–1405

    Article  PubMed  Google Scholar 

  29. Weening JJ, D’ Agati VD, Schuartz MM (2004) Classification of glomerulonephritis revisited in systemic lupus erythematosus. J Am Soc Nephrol 65:521–530

    Google Scholar 

  30. The American College of Rheumatology (2006) Criteria for proliferative response and membranous kidney disease in systemic Lupus Erythematosus Clinical Trials. Arthritis Rheum 54:421–432

    Article  Google Scholar 

  31. Chen Y, Korbet S, Katz R, Schwartz M, Lewis E (2008) For the collaborative study group. Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol 3:46–53

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  32. Ginzler E, Dooley MA, Aranow C, Kim M, Buyon J, Merrill J (2005) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Eng J Med 353:2219–2228

    Article  CAS  Google Scholar 

  33. Isenberg D, Appel GB, Contreras G, Dooley MA, Ginzler E, Jayne D et al (2010) Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology 49:128–140

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Rheumatology Section, Hospital Pablo Tobón Uribe, Calle 78B 69-240, Medellin, Colombia

    Luis Fernando Pinto-Peñaranda, Javier Darío Márquez-Hernández, Carolina Muñoz-Grajales & Carlos Jaime Velásquez-Franco

  2. Coomeva EPS, Calle 33 74B-267, Medellin, Colombia

    Vladimir Duque-Caballero

  3. School of Health Sciences, Universidad Pontificia Bolivariana, Carrera 72A 78B-50, Medellin, Colombia

    Carlos Jaime Velásquez-Franco

Authors
  1. Luis Fernando Pinto-Peñaranda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vladimir Duque-Caballero
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Javier Darío Márquez-Hernández
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Carolina Muñoz-Grajales
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Carlos Jaime Velásquez-Franco
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carlos Jaime Velásquez-Franco.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pinto-Peñaranda, L.F., Duque-Caballero, V., Márquez-Hernández, J.D. et al. Predictive factors for low rate of remission in a population of Colombian patients with severe proliferative lupus nephritis. Clin Rheumatol 34, 897–903 (2015). https://doi.org/10.1007/s10067-015-2864-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-015-2864-7

Keywords

Search

Navigation